14 Best Biotech Stocks to Buy Right Now

Page 1 of 14

In this article, we will take a look at the 14 Best Biotech Stocks to Buy Right Now.

The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late. In particular, the Trump administration has disrupted the industry by reducing research funding, changing vaccine protocols, and supporting legislation to reduce Medicaid spending, among other policies.

Late September 25, President Trump fueled additional upheaval by threatening to put a 100% tariff on imported medications beginning October 1 unless the companies who manufacture them begin constructing plants in the United States.

Meanwhile, one of the most widely utilized analgesics, acetaminophen, commonly known as Tylenol, came under heightened scrutiny, as the FDA began updating its labeling on September 22 to alert consumers of the potential link between Tylenol use while pregnant and a higher likelihood of autism and ADHD in children.

14 Best Biotech Stocks to Buy Right Now

Our Methodology

For our list of the best biotech stocks to buy right now, we started with a list of stocks pulled from ETFs, stock screeners, and web rankings. We then utilized Insider Monkey’s Q2 2025 database to discover the best stocks held by hedge funds. The list is organized in ascending order of hedge fund sentiment around each stock.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

14. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 26

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s collaboration with Sirius on FXI siRNA SRSD107, BMO Capital reaffirmed its Outperform rating and $75 price target on the company’s shares on September 23. The collaboration has resulted in the start of a Phase II trial for the prevention of venous thromboembolism (VTE), which does not include gene editing.

Clinical evidence from studies on atrial fibrillation (AF) and total knee arthroplasty (TKA) indicates that FXI is an appealing target that may upend the $15 billion thromboembolism market, which is currently dominated by medications that target Factor X.

About 40% of individuals with atrial fibrillation are either untreated or only partially treated, according to BMO Capital, which suggests an enormous demand for novel treatments in this area.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification.

Page 1 of 14